Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Common Equity (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Common Equity over the past 10 years, most recently at -$6.9 million for Q4 2023.

  • For Q4 2023, Common Equity fell 120.93% year-over-year to -$6.9 million; the TTM value through Dec 2023 reached -$6.9 million, down 120.93%, while the annual FY2023 figure was -$6.9 million, 120.93% down from the prior year.
  • Common Equity for Q4 2023 was -$6.9 million at Corbus Pharmaceuticals Holdings, down from $312000.0 in the prior quarter.
  • Over five years, Common Equity peaked at $91.5 million in Q1 2021 and troughed at -$6.9 million in Q4 2023.
  • A 5-year average of $39.6 million and a median of $42.1 million in 2019 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: surged 635.27% in 2020 and later tumbled 120.93% in 2023.
  • Year by year, Common Equity stood at $6.2 million in 2019, then surged by 635.27% to $45.3 million in 2020, then skyrocketed by 52.64% to $69.1 million in 2021, then crashed by 52.26% to $33.0 million in 2022, then tumbled by 120.93% to -$6.9 million in 2023.
  • Business Quant data shows Common Equity for CRBP at -$6.9 million in Q4 2023, $312000.0 in Q3 2023, and $9.5 million in Q2 2023.